



(11) **EP 3 292 206 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) International Patent Classification (IPC):
C12N 15/864 ^(2006.01) **A61K 38/47** ^(2006.01)
A61K 48/00 ^(2006.01) **A61K 35/76** ^(2015.01)
A61P 25/16 ^(2006.01) **C12N 9/24** ^(2006.01)

(48) Corrigendum issued on:
09.02.2022 Bulletin 2022/06

(52) Cooperative Patent Classification (CPC):
A61K 48/0058; A61K 35/76; A61K 38/47;
A61P 25/16; C12N 9/2405; C12Y 302/01045;
A01K 2227/105; A01K 2267/0356;
C12N 2750/14143; C12N 2750/14171

(45) Date of publication and mention
of the grant of the patent:
22.12.2021 Bulletin 2021/51

(86) International application number:
PCT/US2016/031223

(21) Application number: **16724546.3**

(87) International publication number:
WO 2016/179497 (10.11.2016 Gazette 2016/45)

(22) Date of filing: **06.05.2016**

(54) **GLUCOCEREBROSIDASE GENE THERAPY FOR PARKINSON'S DISEASE**

GLUCOCEREBROSIDASE GENTHERAPIE VON MORBUS PARKINSON

GLUCOCÉRÉBROSIDASE THERAPIE GENIQUE POUR LA MALADIE DE PARKINSON

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(56) References cited:
WO-A1-2014/071282 WO-A1-2015/060722
US-A1- 2011 038 851

(30) Priority: **07.05.2015 US 201562158244 P**

(43) Date of publication of application:
14.03.2018 Bulletin 2018/11

(73) Proprietors:
• **Takeda Pharmaceutical Company Limited**
Osaka-shi, Osaka (JP)
• **The McLean Hospital Corporation**
Belmont, MA 02478 (US)

- **S. P. SARDI ET AL: "CNS expression of glucocerebrosidase corrects -synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 29, 5 July 2011 (2011-07-05) , pages 12101-12106, XP055298671, US ISSN: 0027-8424, DOI: 10.1073/pnas.1108197108**
- **EMILY M. ROCHA ET AL: "Glucocerebrosidase gene therapy prevents [alpha]-synucleinopathy of midbrain dopamine neurons", NEUROBIOLOGY OF DISEASE., vol. 82, 1 October 2015 (2015-10-01), pages 495-503, XP055298642, GB ISSN: 0969-9961, DOI: 10.1016/j.nbd.2015.09.009**

(72) Inventors:
• **PARK, Yung Hee**
Lexington, MA 02421 (US)
• **ISACSON, Ole**
Belmont, MA 02478 (US)

(74) Representative: **Carpmaels & Ransford LLP**
One Southampton Row
London WC1B 5HA (GB)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 292 206 B8